To verify the involvement of the HSP90AA1/PI3K/AKT signaling pathway as an important metabolic‐related molecular mechanism involved in hUC‐MSCs therapy aimed at improving the pro‐inflammatory microenvironment of SLE, we conducted animal experiments. The gene discussed is HSP90AA1; the disease is systemic lupus erythematosus.